Modelling the consumption of anxiolytics and its addictive behaviour

Abstract

Background

Population-based anxiolytics consumption (AX) is a widely debated subject because long-term AX may lead to tolerance and addiction. This study aims to obtain mathematical models that identify the various behaviours in AX prescription in accordance with gender, age and the continuous prescription of other drugs associated with chronic diseases.

Methods

Data were obtained from an electronic prescriptions database (n = 12,211,992) received by patients (n = 504,224) visiting the Primary Health Care Centres in the province of Castellón (East Spain) in 2009. A linear regression model was used to explain the number of defined daily doses (DDD) of AX prescribed in accordance with age, gender and more than 5 prescriptions of any drug associated with chronic diseases other than AX. We used the logistic regression model to quantify the joint influence of the explanatory variables on the likelihood (L) of prescribing increasingly high DDD of AX.

Results

The mean annual DDD per patient was 133.13, and the DDD prescribed was 38.06 day/1000 inhabitants. Few differences, although significant, in prescriptions per gender were observed; males received fewer prescriptions than females. Conversely, differences in age groups were substantial; the older subjects become, the higher the prescribed DDD, although these differences disappeared after the age of 65. AX use was also positively associated with the presence of comorbidity: depression, psychosis and epilepsy. Sporadic AX prescriptions were not associated with any factor, except continuous use.

Conclusions

The prevalence of prescribing AX in the general population visiting the primary health centres in Castellón is over 16%. Prescriptions and the DDD of AX are barely higher for females than for males, and age is the most influential factor; the older the patient, the higher the number of prescribed DDD. The likelihood of potentially addictive behaviours is higher among the elderly and patients with comorbidity, mainly those patients with other chronic psychiatric conditions.

Artículo completo en ScienceDirect.
Octubre 2011

Artículos completos

Impact of population morbidity on health care costs in a health district.

Pharmaceutical cost and multimorbidity with type 2 diabetes mellitus using electronic health record data.

Análisis de costes en el Área de Imagen Médica de grandes hospitales españoles.

Análisis del gasto sanitario por paciente y riesgo clínico por morbilidad en el departamento de Marina Salud (Alicante).

Predictability of pharmaceutical spending in primary health services using Clinical Risk Groups.

Pharmaceutical cost management in an ambulatory setting using a risk adjustment tool.

Is Health Related Quality of Life (HRQoL) a valid indicator for health systems evaluation?

Atención a mujeres inmigrantes en un programa de mediación intercultural en salud.

Modeling Spanish anxiolytic consumption: Economic, demographic and behavioral influences.

Evaluación de un modelo de predicción del gasto farmacéutico en atención primaria de salud basado en variables demográficas.

Sistema de prescripción y dispensación electrónica en la Agencia Valenciana de Salud.

Incidencia y variabilidad de la incapacidad temporal por trastornos de ansiedad en la Comunidad Valenciana durante el 2009.

Costes y procesos hospitalarios en neurología. Estudio en un hospital de referencia.

Claves para motivar y fidelizar a los médicos especialistas.